Quest Diagnostics (NYSE:DGX) Given New $182.00 Price Target at Truist Financial

Quest Diagnostics (NYSE:DGXGet Free Report) had its price objective increased by equities research analysts at Truist Financial from $172.00 to $182.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “hold” rating on the medical research company’s stock. Truist Financial’s target price indicates a potential upside of 11.81% from the stock’s current price.

A number of other equities analysts also recently issued reports on DGX. Baird R W raised shares of Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 23rd. Barclays raised their target price on Quest Diagnostics from $168.00 to $175.00 and gave the company an “equal weight” rating in a research note on Friday. StockNews.com raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Wednesday. UBS Group boosted their target price on shares of Quest Diagnostics from $165.00 to $166.00 and gave the company a “neutral” rating in a report on Wednesday, October 23rd. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $185.00 price target (up from $175.00) on shares of Quest Diagnostics in a research note on Tuesday, December 10th. Six analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $174.00.

Get Our Latest Stock Analysis on DGX

Quest Diagnostics Trading Down 0.9 %

NYSE DGX opened at $162.77 on Friday. The stock has a market cap of $18.17 billion, a P/E ratio of 21.88, a price-to-earnings-growth ratio of 2.43 and a beta of 0.90. Quest Diagnostics has a fifty-two week low of $123.04 and a fifty-two week high of $167.08. The stock has a 50 day simple moving average of $155.40 and a two-hundred day simple moving average of $153.66. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.17 and a current ratio of 1.25.

Quest Diagnostics (NYSE:DGXGet Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $2.23 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.04. Quest Diagnostics had a return on equity of 15.25% and a net margin of 8.82%. On average, analysts forecast that Quest Diagnostics will post 8.9 earnings per share for the current year.

Insiders Place Their Bets

In other news, CAO Michael J. Deppe sold 18,755 shares of Quest Diagnostics stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $154.05, for a total value of $2,889,207.75. Following the completion of the sale, the chief accounting officer now directly owns 34,941 shares in the company, valued at $5,382,661.05. The trade was a 34.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.79% of the stock is owned by insiders.

Institutional Investors Weigh In On Quest Diagnostics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Landscape Capital Management L.L.C. purchased a new stake in Quest Diagnostics during the 3rd quarter valued at $1,363,000. Natixis Advisors LLC increased its position in Quest Diagnostics by 7.7% during the third quarter. Natixis Advisors LLC now owns 92,830 shares of the medical research company’s stock valued at $14,412,000 after acquiring an additional 6,619 shares during the last quarter. Sanctuary Advisors LLC lifted its holdings in Quest Diagnostics by 85.5% in the third quarter. Sanctuary Advisors LLC now owns 17,969 shares of the medical research company’s stock valued at $2,940,000 after acquiring an additional 8,282 shares during the period. BankPlus Wealth Management LLC purchased a new position in Quest Diagnostics in the fourth quarter worth about $355,000. Finally, Icon Wealth Advisors LLC grew its stake in shares of Quest Diagnostics by 8,669.8% during the 3rd quarter. Icon Wealth Advisors LLC now owns 62,178 shares of the medical research company’s stock valued at $9,653,000 after purchasing an additional 61,469 shares during the period. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Company Profile

(Get Free Report)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Further Reading

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.